Replies to post #161743 on Biotech Values

[DewDiligence]

AZN/(AMRN)—Not without a successful outcomes study of some sort...

The sales projections for Epanova* have come down a bit since you posted. Vascepa’s underwhelming launch might have something to do with it, LOL.

*Thomson Reuters has a consensus of $322M annually by 2018 (#msg-101629554).